WHO ICTRP trial
Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to…
CTIS2025-520688-42-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2025-520688-42-00 |
|---|---|
| Public title | Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS |
| Scientific title | A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS) - PHENOALS-001 |
| Primary sponsor | Phenonet Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | United States;Serbia;Czechia;Poland;Spain;Germany |
| Conditions | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 27.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] |
| Interventions | Product Name: Placebo capsule, oral inhalation via DPI, Product Code:N/A, Pharmaceutical Form: N/A, Other descriptive name: N/A , Strength: , Pharmaceutical form of the placebo: N/A , Product Name: PHENOGENE-1a, Product Code:PRD12405328… |
| Registration date | Jun 30, 2025 |
| Target size | 108 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: